Chiral resolving agents — why tartrates still matter in 2026
A primer on the chiral chemistry segment Laksh Finechem has worked in for years — diethyl L tartrate, diisopropyl L tartrate and where Indian manufacturers genuinely compete.
When we received a Star Manufacturer designation for the tartrate family — Di Ethyl D Tartrate, Di Ethyl L Tartrate, Ethyl Glyoxylate 50% Solution — it was a recognition that a small, focused Indian fine-chemicals manufacturer can compete globally in chiral chemistry without ever needing to be the largest player in any segment. I want to walk through why this category still matters in 2026, and what an Indian manufacturer has to bring to it.
The role of chirality in modern pharma
Roughly half of the small-molecule pharmaceutical actives on the market today are single-enantiomer compounds. The wrong enantiomer can be ineffective at best and harmful at worst. Chiral resolution — separating one stereoisomer from another — is therefore at the heart of much modern pharmaceutical chemistry. Chiral resolving agents (CRAs) are the reagents that make this practical.
Tartrate-based CRAs — Diethyl L Tartrate, Diisopropyl L Tartrate, Di Butyl L Tartrate, Dimethyl L Tartrate — have been workhorses of this chemistry for decades. They are not the newest tools available, but they remain among the most reliable and economically sensible for a wide range of resolutions.
Where Indian manufacturers compete
The global tartrate-CRA market is mature. The major customers — pharmaceutical innovators, generic manufacturers, contract research organisations — buy on documented purity, batch-to-batch consistency, and supplier reliability across decades. An Indian manufacturer in this segment competes on three things. One — pharma-grade purity that holds across batches without drift. Two — packaging discipline (50 kg drums versus smaller research lab quantities, the right desiccant handling, the right humidity controls). Three — responsiveness on custom specifications.
The Indian price advantage in this segment is real but not the headline. The headline is reliability — the customer who built their resolution process around your tartrate three years ago does not want to re-validate against a new source. Long customer relationships compound in this category like in few others.
The Star Manufacturer designation
Trade-platform certifications like the Star Manufacturer designation matter primarily for one reason: they signal to a new customer that the supplier has been validated through hundreds of transactions in a category. For a category like tartrates — where customer chemistry is long-running and audit cycles are the norm — the certification is shorthand for 'this is a serious supplier'. We were recognised for the tartrate family because we had committed to it as a category rather than rotating through whatever segment paid best in a given month. Specialisation, over a decade, compounds.
What founders entering this category need to know
If you are an Indian fine-chemicals founder considering entry into chiral resolving agents or related tartrate chemistry, three pieces of operating advice. One — the volume per molecule is moderate. Build the line for purity and documentation, not for tonnage. Two — invest in the QC instrumentation upfront. Optical purity measurement is what your customer cares about; getting it right is the table stake. Three — commit to the category for at least five years before judging the economics. The category compounds slowly and rewards specialists. Tourists in chiral chemistry rarely make it past year two.
Where the segment goes
Chiral chemistry continues to grow because pharmaceutical synthesis continues to grow toward single-enantiomer molecules. Newer chiral technologies — biocatalysis, asymmetric hydrogenation, asymmetric organocatalysis — are taking market share at the high end. But classical CRA-based resolution still serves a wide swath of pharmaceutical synthesis, particularly in generic and intermediate chemistry where the cost-effectiveness of a well-run tartrate plant is hard to beat. For Indian manufacturers in this segment, the next decade is steady, unspectacular, and reliable. That is exactly the right description of a good fine-chemicals business.
Got a question on what you've just read — or a project that touches one of the categories above? Write directly to the office.
First-generation Indian industrialist. Founder and Managing Director of Laksh Finechem — a WHO-GMP, FDA and ISO-certified manufacturer of APIs, iodine derivatives and specialty chemicals.